McKesson Past Earnings Performance

Past criteria checks 2/6

McKesson has been growing earnings at an average annual rate of 38.5%, while the Healthcare industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 7.1% per year.

Key information

38.5%

Earnings growth rate

41.8%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate7.1%
Return on equityn/a
Net Margin1.0%
Next Earnings Update07 Aug 2024

Recent past performance updates

McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Feb 16
McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Recent updates

With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For

May 09
With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For

Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

Mar 14
Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

McKesson: GLP-1 Contributed More Than 1/3 Of Growth

Feb 19

McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Feb 16
McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking

Jan 29
Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking

McKesson: Why The Company Is Too Richly Valued

Jan 19

If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity

Nov 20
If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity

McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase

Nov 08

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?

Oct 30
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?

McKesson: Still Trading For A Huge Discount

Sep 06

Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Aug 21
Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?

Jul 27
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?

McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation

Jun 28

Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

May 23
Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?

Apr 17
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?

Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?

Feb 22
Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?

McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth

Feb 08

McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M

Feb 01

McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price

Jan 12
McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price

5 Reasons Why I Am Considering Adding McKesson To My Portfolio

Dec 27

McKesson Corporation: Still Trading Below Intrinsic Value

Dec 13

Duration: The Time Bomb In Your Portfolio - McKesson And PayPal In Focus

Oct 08

McKesson extends distribution partnership with CVS Health

Sep 29

An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued

Sep 19
An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued

McKesson to acquire Rx Savings Solutions in $875M deal

Sep 19

Cardinal Health, McKesson hit 52-week highs; up 35% and 50% YTD

Aug 15

McKesson raises fiscal 2023 adjusted diluted EPS following strong quarterly results

Aug 03

McKesson raises dividend by 15% to $0.54/share

Jul 25

McKesson Is Still An Attractive Dividend Growth Stock

Jul 10

McKesson: Best Of Breed In Drug Distributor Oligopoly

Jun 20

Revenue & Expenses Breakdown

How McKesson makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSE:MCK Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24308,9513,0028,0100
31 Dec 23301,5062,9987,7850
30 Sep 23291,0983,4877,8380
30 Jun 23284,0403,7557,8810
31 Mar 23276,7113,5637,9800
31 Dec 22273,9033,1468,2580
30 Sep 22272,0272,0618,4380
30 Jun 22268,4461,3968,7020
31 Mar 22263,9661,1198,9370
31 Dec 21257,0061,4158,9180
30 Sep 21250,991-4,8048,9260
30 Jun 21245,223-4,4948,9190
31 Mar 21238,228-4,5388,7910
31 Dec 20237,621-4,1898,6960
30 Sep 20234,1942,2288,8750
30 Jun 20231,0029228,8640
31 Mar 20231,0519068,9070
31 Dec 19224,945-9059,64171
30 Sep 19221,981-6269,16071
30 Jun 19217,4406018,64271
31 Mar 19214,319338,4370
31 Dec 18213,518-3198,362125
30 Sep 18210,9271138,197125
30 Jun 18209,913-3848,300125
31 Mar 18208,357628,138125
31 Dec 17205,4424,8057,464341
30 Sep 17201,9554,5397,503341
30 Jun 17199,8514,8467,317341
31 Mar 17198,5335,1947,447341
31 Dec 16196,4982,0517,149392
30 Sep 16194,2672,0447,264392
30 Jun 16193,0712,3597,283392
31 Mar 16190,8842,2907,379392
31 Dec 15189,1312,2377,573392
30 Sep 15187,7162,0907,342392
30 Jun 15183,1151,9507,781392
31 Mar 15179,0451,7757,901392
31 Dec 14171,9521,7807,323457
30 Sep 14159,8041,4626,932457
30 Jun 14148,6291,4026,143457
31 Mar 14137,3921,4195,388457
31 Dec 13130,0761,2784,675433
30 Sep 13126,8391,4204,554433
30 Jun 13123,6091,3964,298433

Quality Earnings: MCK has high quality earnings.

Growing Profit Margin: MCK's current net profit margins (1%) are lower than last year (1.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MCK's earnings have grown significantly by 38.5% per year over the past 5 years.

Accelerating Growth: MCK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MCK had negative earnings growth (-15.7%) over the past year, making it difficult to compare to the Healthcare industry average (15.1%).


Return on Equity

High ROE: MCK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.